Page 40 - IMO-2-3

Innovative Medicines & Omics Tyrosine kinases: Structure, mechanism, and therapeutics

generate figures. For protein–protein interaction studies, post-translational modifications reveals shared patterns of
we used the HADDOCK online portal (https://rascar. protein regulation. Cell. 2023;186(18):3945-3967.e26.
science.uu.nl/haddock2.4/). For the chemo- and immuno- doi: 10.1016/j.cell.2023.07.013
therapy drug search, we referred to published literature, 6. Yoshida K, Yokoi A, Yamamoto T, et al. Aberrant
Drugs.com, antibodysoci-ty.org, and cancerresearch.org.
activation of cell-cycle-related kinases and the potential
Funding therapeutic impact of PLK1 or CHEK1 Inhibition in uterine
leiomyosarcoma. Clin Cancer Res. 2022;28(10):2147-2159.
None.
doi: 10.1158/1078-0432.Ccr-22-0100
Conflict of interest 7. Dutta H, Jain N. Post-translational modifications and their
implications in cancer. Front Oncol. 2023;13:1240115.
The authors declare that they have no competing interests.
doi: 10.3389/fonc.2023.1240115
Author contributions 8. Wilks AF. Structure and function of the protein tyrosine
Conceptualization: Eswar Kumar Nadendla, Raghavendra kinases. Prog Growth Factor Res. 1990;2(2):97-111.
Sashi Krishna Nagampalli doi: 10.1016/0955-2235(90)90026-G
Visualization: Eswar Kumar Nadendla 9. Aschner Y, Downey GP. The importance of tyrosine
Writing–original draft: Eswar Kumar Nadendla, Gangadhar phosphorylation control of cellular signaling pathways in
P. Vadla, Raghavendra Sashi Krishna Nagampalli respiratory disease: pY and pY Not. Am J Respir Cell Mol
Writing–review & editing: Eswar Kumar Nadendla, Biol. 2018;59(5):535-547.
Manohar Radhakrishnan, Raghavendra Sashi Krishna doi: 10.1165/rcmb.2018-0049TR
Nagampalli
10. Yao Z, Stagljar I. Multiple functions of protein phosphatases
Ethics approval and consent to participate in receptor tyrosine kinase signaling revealed by interactome
analysis. Mol Cell Oncol. 2017;4(3):e1297101.
Not applicable.
doi: 10.1080/23723556.2017.1297101
Consent for publication 11. Solouki S, August A, Huang W. Non-receptor tyrosine kinase

Not applicable. signaling in autoimmunity and therapeutic implications.
Pharmacol Ther. 2019;201:39-50.
Availability of data doi: 10.1016/j.pharmthera.2019.05.008
The HADDOCK-generated Src: PTPa complex model 12. Tomuleasa C, Tigu A-B, Munteanu R, et al. Therapeutic
shown in the review is available from the corresponding advances of targeting receptor tyrosine kinases in cancer.
authors on request. Signal Transduct Target Ther. 2024;9(1):201.

References doi: 10.1038/s41392-024-01899-w
13. Wu F, Yang J, Liu J, et al. Signaling pathways in cancer-
1. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. associated fibroblasts and targeted therapy for cancer. Signal
Nature. 2001;411(6835):355-365. Transduct Target Ther. 2021;6(1):218.
doi: 10.1038/35077225
doi: 10.1038/s41392-021-00641-0
2. Hunter T. Signaling--2000 and beyond. Cell. 2000; 14. Hunter T, Cooper JA. Protein-tyrosine kinases. Annu Rev
100(1):113-127.
Biochem. 1985;54:897-930.
doi: 10.1016/s0092-8674(00)81688-8
doi: 10.1146/annurev.bi.54.070185.004341
3. Schlessinger J. Cell signaling by receptor tyrosine kinases. 15. Sawyers CL. Rational therapeutic intervention in
Cell. 2000;103(2):211-225.
cancer: Kinases as drug targets. Curr Opin Genet Dev.
doi: 10.1016/s0092-8674(00)00114-8 2002;12(1):111-115.
4. Zhao M, Jung Y, Jiang Z, Svensson KJ. Regulation of energy doi: 10.1016/s0959-437x(01)00273-8
metabolism by receptor tyrosine kinase ligands. Front 16. Zhang N, Li Y. Receptor tyrosine kinases: Biological
Physiol. 2020;11:354.
functions and anticancer targeted therapy. MedComm
doi: 10.3389/fphys.2020.00354 (2020). 2023;4(6):e446.
5. Geffen Y, Anand S, Akiyama Y, et al. Pan-cancer analysis of doi: 10.1002/mco2.446

Volume 2 Issue 3 (2025) 34 doi: 10.36922/IMO025200022